Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Bora Acquires Six US Brand Product Licenses, Rights
Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Product Name : Zestril
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 18, 2023
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : TWi Pharmaceuticals
Deal Size : $38.5 million
Deal Type : Acquisition
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : ClinPharmInvest
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Aztiq Buys 17% Stake in Alvogen US
Details : Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.
Product Name : Zestril
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : AZTIQ PHARMA
Deal Size : $350.0 million
Deal Type : Acquisition
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market
Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2020
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Lupus Research Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Centrally Acting ACE Inhibition in SLE
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 24, 2020
Lead Product(s) : Lisinopril
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Lupus Research Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Chinese University of Hong Kong
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-induced Cardiomyopathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 08, 2018
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Lisinopril
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : National Institute of Diabetes and Digestive and Kidney Diseases | Aminu Kano Teaching Hospital | Frederick National Laboratory | Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2013
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
HALT Progression of Polycystic Kidney Disease Study B
Details : Lisinopril is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Kidney Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2013
Lead Product(s) : Lisinopril
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Boehringer Ingelheim GmbH | Merck & Co | Polycystic Kidney Disease Foundation | The University of Pittsburgh School of Medicine | Washington University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
